Updates are available Correction dated 2024-06-12

Article History

Received: 16 June 2023

Accepted: 27 July 2023

First Online: 7 August 2023

Change Date: 12 June 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10120-024-01519-0

Declarations

:

: Yasuhiro Kodera reports grants from Kaken Pharma, Otsuka, Shionogi, Nihon Kayaku, Daiichi Sankyo, Taiho Pharma, Abbot, Pfizer, and Bayer, and grants and personal fees from Chugai Pharma, Daiichi Sankyo, Taiho Pharma, Abbvie, Lilly Japan, Yakult, Ono Pharmaceutical, Bristol-Myers Squibb, Amgen, and MSD, and takes a role of Advisory Board for Daiichi Sankyo. Kazuhiro Yoshida reports grands from Abbott, Asahi Kasei Pharma, Eisai, Johnson & Johnson, Kaken Pharma, and Kyowa Kirin, and grants and personal fees from Chugai Phamaceutical, Covidien, Daiichi Sankyo, Eli Lilly Japan, Nippon Kayaku, Otsuka Pharm, Takeda, TERUMO, Tsumura, and Yakult, and personal fees from AMCO Inc., Astellas Pharma, Bristol-Meyers Squibb, EA Pharma, MSD, and Ono Pharmaceutical. Takeshi Sano reports personal fees from Taiho Pharmaceutical. Wataru Ichikawa reports grants from Daiichi Sankyo, Shionogi, Takeda, grants and personal fees from Taiho Pharmaceutical, Chugai Pharmaceutical, and personal fees from Yakult, Bristol-Meyers Squibb, Merck Biopharma, and AstraZeneca. Yoshihiro Kakeji reports personal fees from Taiho Pharmaceutical, and takes a role of the Chairman of the Board of Directors for Japanese Gastric Cancer Association. Yu Sunakawa reports grants from Sanofi, Ohtsuka Pharmaceutical, and Lilly Japan, and grants and personal fees from Lilly Japan, Chugai Pharmaceutical, Takeda, Taiho Pharmaceutical, and personal fees from Bristol-Myers Squibb, Ono Pharmaceutical, Merck Biopharma, Bayer, Daiichi-Sankyo, MSD, Sysmex, Guardant Health.

: The study was conducted in accordance with the principles of the Declaration of Helsinki 2013 and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. The study protocol was approved by the institutional review board of each participating hospital. Written informed consent was obtained from all patients prior to enrollment. Data were maintained by the independent JACCRO GC-07 data center and analyzed by the JACCRO Statistical Analysis Department.